Key Takeaway: CG Oncology is set to present at the ASCO-GU 2024 meeting, showcasing their latest research developments. This follows their recent positive results from the CORE-1008 Phase 2 trial, which evaluates a new therapy for high-risk bladder cancer patients. The company is actively participating in various conferences to share their findings.
Price reaction · baseline $40.225 (2025-11-11T17:31:00.000Z) · hit during market hours · 2 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-3.4%
Market Sentiment Analysis
POSITIVE FACTORS
CG Oncology reports positive results from CORE-1008 trial.
Upcoming presentations at major conferences highlight ongoing research.
Recognition of award recipients for NMIBC research indicates progress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer
Full Press Release Details
by admin | Nov 11, 2025 | Uncategorized
Recent Posts
• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation
Recent Comments
Frequently Asked Questions
What is the focus of CG Oncology's presentation at ASCO-GU 2024?
CG Oncology will present findings from their CORE-1008 Phase 2 trial.
What recent results did CG Oncology report?
They reported positive results from the CORE-1008 trial for high-risk bladder cancer.
What other events is CG Oncology participating in?
CG Oncology is also presenting at various investor conferences in June.
What recognition did CG Oncology recently announce?
They announced the award recipients for the NMIBC research fellowship.